Bukwang Pharm
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more
Bukwang Pharm (003000) - Total Liabilities
Latest total liabilities as of September 2025: ₩132.16 Billion KRW
Based on the latest financial reports, Bukwang Pharm (003000) has total liabilities worth ₩132.16 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bukwang Pharm - Total Liabilities Trend (2007–2024)
This chart illustrates how Bukwang Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bukwang Pharm Competitors by Total Liabilities
The table below lists competitors of Bukwang Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Archi Indonesia Tbk PT
JK:ARCI
|
Indonesia | Rp609.78 Million |
|
Jiangsu Jiangnan High Polymer Fiber Co Ltd
SHG:600527
|
China | CN¥87.49 Million |
|
Kelsian Group Ltd
AU:KLS
|
Australia | AU$1.56 Billion |
|
Fujimori Kogyo Co. Ltd
F:FJ3
|
Germany | €46.45 Billion |
|
Jiu Han System Technology Co. Ltd.
TWO:6903
|
Taiwan | NT$1.49 Billion |
|
VIA Technologies Inc
TW:2388
|
Taiwan | NT$11.60 Billion |
|
New East New Materials Co Ltd
SHG:603110
|
China | CN¥101.55 Million |
|
Shanghai Titan Scientific Co. Ltd. A
SHG:688133
|
China | CN¥2.00 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Bukwang Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bukwang Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bukwang Pharm (2007–2024)
The table below shows the annual total liabilities of Bukwang Pharm from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩129.03 Billion | -33.74% |
| 2023-12-31 | ₩194.75 Billion | +50.88% |
| 2022-12-31 | ₩129.08 Billion | +9.99% |
| 2021-12-31 | ₩117.36 Billion | -9.57% |
| 2020-12-31 | ₩129.78 Billion | +109.15% |
| 2019-12-31 | ₩62.05 Billion | -22.61% |
| 2018-12-31 | ₩80.17 Billion | +221.64% |
| 2017-12-31 | ₩24.93 Billion | +8.38% |
| 2016-12-31 | ₩23.00 Billion | -19.32% |
| 2015-12-31 | ₩28.51 Billion | +6.30% |
| 2014-12-31 | ₩26.82 Billion | -1.18% |
| 2013-12-31 | ₩27.14 Billion | -52.00% |
| 2008-12-31 | ₩56.54 Billion | +27.39% |
| 2007-12-31 | ₩44.39 Billion | -- |